IBRX - ImmunityBio, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
IBRX price evolution
IBRX
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $2.06 | $2.14 | $3.17 | $4.66 |
| Inventory | $1.81 | |||
| Total current assets | $242.83 | $195.72 | $294.08 | $215.08 |
| Long term investments | ||||
| Property, plant & equipment | $175.79 | $178.75 | $182.68 | $187.89 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $444.32 | $400.68 | $504.45 | $432.42 |
| Current liabilities | ||||
| Accounts payable | $20.32 | $13.87 | $9.2 | $19.82 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $62.11 | $53.76 | $58.28 | $90.32 |
| Long term debt | $956.26 | $850.5 | $836.95 | $673.59 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $1142.71 | $1092.69 | $1091.44 | $844.14 |
| Shareholders' equity | ||||
| Retained earnings | -$3230.36 | -$3095.79 | -$2961.68 | -$2728.29 |
| Other shareholder equity | -$0.01 | -$0.01 | $0.01 | $0.79 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $11.44 | |||
| Short term investments | ||||
| Net receivables | $3.17 | $1.89 | $1.33 | $5 |
| Inventory | ||||
| Total current assets | $294.08 | $140.58 | $334.35 | $75.5 |
| Long term investments | ||||
| Property, plant & equipment | $182.68 | $189.58 | $119.17 | $53.93 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $76.36 | |||
| Total investments | ||||
| Total assets | $504.45 | $362.36 | $468.91 | $151.86 |
| Current liabilities | ||||
| Accounts payable | $9.2 | $21.02 | $11.42 | $9.37 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $58.28 | $500.86 | $369 | $24.65 |
| Long term debt | $836.95 | $241.34 | $306.35 | $254.4 |
| Total noncurrent liabilities | $9.81 | |||
| Total debt | ||||
| Total liabilities | $1091.44 | $809.68 | $711.08 | $34.47 |
| Shareholders' equity | ||||
| Retained earnings | -$2961.68 | -$2378.49 | -$1961.92 | -$754.57 |
| Other shareholder equity | $0.01 | $0.18 | $0 | -$0.12 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.12 | $0.04 | $0.01 | |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $90.92 | $79.66 | $95.98 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$15.9 | -$11.04 | -$5.78 | |
| Net income | ||||
| Net income | -$110.94 | -$94.59 | -$102.83 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.11 | $0.04 | ||
| Cost of revenue | ||||
| Gross Profit | $0.11 | $0.04 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $91.74 | $67.85 | ||
| Operating income | -$91.63 | -$67.81 | ||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.01 | -$0.1 | ||
| Interest expense | $0.04 | $0.02 | ||
| Net income | ||||
| Net income | -$92.38 | -$65.79 | ||
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $46.19 | $47.36 | -$69.31 | -$84.89 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $123.67 | -$0.31 | -$0.3 | $505.44 |
| Effect of exchange rate | $0.12 | $0.08 | -$0.17 | $0.05 |
| Change in cash and equivalents | -$76.8 | -$119.06 | -$144.71 | $146.18 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Net income | -$92.38 | -$65.79 | ||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$70.45 | -$61.36 | ||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$84.89 | -$20.59 | $21.46 | $57.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $505.44 | $86.97 | $38.59 | -$0.77 |
| Effect of exchange rate | $0.05 | |||
| Change in cash and equivalents | $146.18 | -$4.07 | -$1.31 | -$7.05 |
News
Fundamentals
| Market cap | $3.48B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 691.79M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 78.79% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.91 |
| Quick ratio | 3.88 |